Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood syringe stability study ends early – no major findings

NCT ID NCT07491731

Knowledge-focused Sponsor: Radiometer Medical ApS Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at how stable 17 different blood measurements are when stored in PICO A and safePICO A syringes for up to 45 minutes. It involved 43 adults in intensive care who already had blood lines. The study was terminated early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

43 people

The number who actually took part.

Started

Oct 2025

Finished

Jan 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients 18 years or older, critically ill, but still able to understand and sign the informed consent form and admitted to the hospital having an arterial catheter line established as part of standard of care to minimize the risk to the patient when having blood samples drawn. To reach reportable concentrations of the 17 parameters covering the reportable range as much as possible the subject will be a patient in the intensive care unit or another unit corresponding to the emergency care.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Subjects must meet all the criteria listed below to be eligible for participation in the study. 1. Subject must be 18 years of age or older. 2. Subject must have an arterial and/or venous line established as a part of the standard of care. 3. Subject evaluated by the principal investigator or designee as suitable for the study according to the protocol. Exclusion Criteria: Subjects meeting any of the criteria listed below will not be eligible for participation in the study. 1. Subjects, who are pregnant or breastfeeding. 2. Subjects who have been previously enrolled into this study. 3. Subjects exposed to following substances within the last 72 hours: * Acetylsalicylic Acid Sodium Salt at dose equal or above 1 gram/day * Acetylcysteine * Fluorescein dye * Patent Blue dye

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Critical care, intensive care are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Critical care, intensive care

Contacts and locations

Locations

  • Bispebjerg Hospital, Itensiv afsnit

    København NV, 2400, Denmark

  • Hvidovre Hospital

    Hvidovre, Denmark

  • Sjællands Universitetshospital Køge

    Køge, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.